21.25
1.59 (8.09%)
| Penutupan Terdahulu | 19.66 |
| Buka | 19.81 |
| Jumlah Dagangan | 355,690 |
| Purata Dagangan (3B) | 582,770 |
| Modal Pasaran | 397,720,960 |
| Harga / Buku (P/B) | 1.50 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| EPS Cair (TTM) | -3.14 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.87% |
| Nisbah Semasa (MRQ) | 22.92 |
| Aliran Tunai Operasi (OCF TTM) | -62.89 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -69.56 M |
| Pulangan Atas Aset (ROA TTM) | -22.89% |
| Pulangan Atas Ekuiti (ROE TTM) | -41.60% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Tectonic Therapeutic, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | -2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | 2.0 |
| Purata | -0.13 |
|
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 38.29% |
| % Dimiliki oleh Institusi | 59.27% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Bollard Group Llc | 30 Sep 2025 | 302,953 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 01 Dec 2025 | Pengumuman | Tectonic Therapeutic to Participate in December Investor Conferences |
| 06 Nov 2025 | Pengumuman | Tectonic Therapeutic Announces Third Quarter 2025 Financial Results and Recent Business Highlights |
| 29 Oct 2025 | Pengumuman | Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |